Table 1 Pertussis vaccine efficacy studies
Study (year) | Country | Type of analysis | Included partecipans | Dose schedule | Type of vaccine | Efficacy of vaccine (95% CI) |
|---|---|---|---|---|---|---|
AHGSPV 1988 | USA | Double bind parallel group RCT | Age 5 to 11 months | 2 doses (entry + 8 to 12 week later) | aP: JNIH7 | 78% (57-88%) |
aP: JNIH6 | 78% (58-89%) | |||||
Trollfors 1995 | Sweden | Double bind parallel group \ RCT | Full term, healthy infants | 3 doses (3, 5, 12 months) | DTaP: Amvax | 71% (63-78%) |
Greco 1996 | Italy | Double bind parallel group RCT | Age 6 to 12 weeks and weight >3rd percentile | 3 doses (6 to 12, 13 to 20, and 21 to 28 weeks) | DTaP: SKB | 84% (76-89%) |
DTaP: CB | 84% (76-90%) | |||||
DTwP: CON | 36% (13-50%) | |||||
Gustafsson 1996 | Sweden | Double bind parallel group RCT | Age 2 to 3 months | 3 doses (2, 4, 6 months) | DTaP: SKB | 59% (51-66%) |
DTaP: CON | 85% (81-89%) | |||||
DTwP: CON | 48% (37-58%) | |||||
Simondon 1997 | Senegal | Parallel group RCT | Age 2 months | 3 doses (2, 4, 6 months) | DTaP: Pasteur-Merieux | 85% (66-93%) |
DTwP: Pasteur-Merieux | 96% (86-99%) | |||||
Olin 1997 | Sweden | RCT | Age 2–3 months | 3 doses (3, 5, 12 months or 2, 4, 6 months) | 3-component DTaP | 72% |
5-component | 85% | |||||
DTaP | Â | |||||
DTwP | 89% | |||||
PVSG 1998 | Germany | Parallel group RCT | Age 2 to 4 months | 4 doses (2 to 4, 4 to 6, 6 to 8, 12 to 14, and 15 to 18 months) | DTaP: Lederle/ Takeda | 79% (72-85%) |
DTwP: Lederle | 84% (77-89%) | |||||
Ward 2006 | USA | Multicenter, double-blind RCT | Age 15 to 65 years | A single dose of a 3-component aP vaccine | aP (PT, FHA, PRN) | 92% (32-99%) |